Here, we demonstrate the capacity of an IgA2 variant of daratumumab to trigger myeloid cell-mediated ADCP and ADCC against T-ALL cells when combined with CD47 blockade. This evidence concerns the gene CD47 and acute lymphoblastic leukemia.